Literature DB >> 32331545

Recent Advances in Mode of Action and Biosynthesis Studies of the Clinically Used Antibiotic Fidaxomicin.

Andrea Dorst1, Erik Jung1, Karl Gademann2.   

Abstract

The natural product antibiotic fidaxomicin is a marketed drug for the treatment of bacterial infections in the gut. Due to its promising in vitro activities against Mycobacterium tuberculosis, the development of next generation fidaxomicin analogs is of great interest. This article reviews the most recent advances, including the elucidation of a unique mode of action by cryo-EM structures, and the efforts towards the clarification of the biosynthetic pathway. Moreover, known fidaxomicin analogs and their reported antibacterial activities are summarized.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32331545     DOI: 10.2533/chimia.2020.270

Source DB:  PubMed          Journal:  Chimia (Aarau)        ISSN: 0009-4293            Impact factor:   1.509


  2 in total

1.  Semisynthetic Analogs of the Antibiotic Fidaxomicin-Design, Synthesis, and Biological Evaluation.

Authors:  Andrea Dorst; Regina Berg; Christoph G W Gertzen; Daniel Schäfle; Katja Zerbe; Myriam Gwerder; Simon D Schnell; Peter Sander; Holger Gohlke; Karl Gademann
Journal:  ACS Med Chem Lett       Date:  2020-10-14       Impact factor: 4.345

2.  Going Retro, Going Viral: Experiences and Lessons in Drug Discovery from COVID-19.

Authors:  Bing Wang; Dmitri Svetlov; Dylan Bartikofsky; Christiane E Wobus; Irina Artsimovitch
Journal:  Molecules       Date:  2022-06-14       Impact factor: 4.927

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.